C Blank
Overview
Explore the profile of C Blank including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, et al.
Ann Oncol
. 2024 Nov;
36(1):10-30.
PMID: 39550033
No abstract available.
2.
Quack L, Glatter S, Wegener-Panzer A, Cleaveland R, Bertolini A, Endmayr V, et al.
Eur J Paediatr Neurol
. 2024 May;
51:151-152.
PMID: 38692980
No abstract available.
3.
Quack L, Glatter S, Wegener-Panzer A, Cleaveland R, Bertolini A, Endmayr V, et al.
Eur J Paediatr Neurol
. 2024 Jan;
47:118-130.
PMID: 38284996
Background: Acute cerebellitis (AC) in children and adolescents is an inflammatory disease of the cerebellum due to viral or bacterial infections but also autoimmune-mediated processes. Objective: To investigate the frequency...
4.
Long G, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, et al.
Ann Oncol
. 2021 Oct;
33(2):204-215.
PMID: 34710571
Background: Antitumor activity of ipilimumab or BRAF ± MEK inhibitors (BRAFi ± MEKi) following pembrolizumab administration in melanoma is poorly characterized. Patients And Methods: In the phase III KEYNOTE-006 study,...
5.
Blank C, DeCroo I, Weyers B, van Avermaet L, Tilleman K, van Rumste M, et al.
Eur J Obstet Gynecol Reprod Biol
. 2020 Sep;
253:198-205.
PMID: 32877773
Objective: The aim of this study was to evaluate the predictive value of the dynamic morphological development process between cleavage-stage and blastocyst-stage embryos. Study Design: A retrospective study was executed...
6.
Blank C, Ahuja R, McGovern D, Gaschen F, Gaschen L
J Small Anim Pract
. 2020 Aug;
61(11):717.
PMID: 32856737
No abstract available.
7.
Ugurel S, Schadendorf D, Horny K, Sucker A, Schramm S, Utikal J, et al.
Ann Oncol
. 2020 Jan;
31(1):144-152.
PMID: 31912789
Background: Programmed cell death protein 1 (PD-1) checkpoint inhibition has recently advanced to one of the most effective treatment strategies in melanoma. Nevertheless, a considerable proportion of patients show upfront...
8.
Xu Z, Lay B, Oexle N, Drack T, Bleiker M, Lengler S, et al.
Epidemiol Psychiatr Sci
. 2018 Feb;
28(4):458-465.
PMID: 29382403
Aims: Compulsory admission can be experienced as devaluing and stigmatising by people with mental illness. Emotional reactions to involuntary hospitalisation and stigma-related stress may affect recovery, but longitudinal data are...
9.
Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob J, Nathan P, et al.
Eur J Cancer
. 2017 Mar;
75:313-322.
PMID: 28264791
Background: Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these...
10.
McArthur G, Maio M, Arance A, Nathan P, Blank C, Avril M, et al.
Ann Oncol
. 2016 Dec;
28(3):634-641.
PMID: 27993793
Background: Vemurafenib has shown activity in patients with BRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients with/without prior treatment for BM. Methods: Patients...